Winkels W, Klutmann M, Bias R, Wessolowski T, Simon H
Medizinische Klinik I, Krankenhaus Düren, RWTH Aachen.
Pneumologie. 1997 Aug;51 Suppl 3:802-3.
Nasal CPAP is a well documented successful therapy for obstructive sleep apnoea syndrome (OSAS), but adverse effects are common and the compliance is 80 percent or less. We investigated the value of an oral device called "Snor Ex"). Eleven obese patients with severe OSAS were examined. Complete polysomnographic studies were performed while sleeping one night without therapy, with nCPAP and after an adaptation period with Snor Ex, respectively. The apopnoeahypopnoea index and the minimal SaO2 could be normalised for all patients using CPAP but only for three patients with Snor Ex. Nine patients tolerated nCPAP and Snor-Ex, respectively. We conclude that this oral device is a successful therapy for only few patients with OSAS.
鼻持续气道正压通气（Nasal CPAP）是治疗阻塞性睡眠呼吸暂停综合征（OSAS）的一种有充分文献记载的成功疗法，但不良反应很常见，依从性为80%或更低。我们研究了一种名为“Snor Ex”的口腔矫治器的价值。对11名重度OSAS肥胖患者进行了检查。分别在未治疗、使用鼻持续气道正压通气（nCPAP）以及使用Snor Ex适应一段时间后，各进行了一晚睡眠期间的完整多导睡眠图研究。使用CPAP时，所有患者的呼吸暂停低通气指数和最低血氧饱和度（SaO2）均可恢复正常，但使用Snor Ex时只有3名患者可恢复正常。分别有9名患者耐受nCPAP和Snor Ex。我们得出结论，这种口腔矫治器仅对少数OSAS患者是一种成功的治疗方法。
